Recent Study Published in Journal of Clinical Oncology Highlights Importance of Prognostic Biomarker for Uveal Melanoma
The results of the Collaborative Ocular Oncology Study Number 2 (COOG2) were published in the July 2024 issue of the Journal of Clinical Oncology and validated the prognostic accuracy of the integrated
read more
Dr. Abbey First in the World to Administer Novel Trispecific Fusion Antibody EB-105 for Diabetic Macular Edema as Part of Phase Ib LOTUS Clinical Trial
On July 9, Texas Retina Associates Director of Clinical Research for Dallas Ashkan Abbey, MD, dosed the first patient in the Phase Ib LOTUS trial of EB-105, the world’s first pentavalent trispecific
read more
Dr. Anand Presented Interim Study Results of New Gene Therapy for X-linked Retinitis Pigmentosa at ASRS 2024 Annual Meeting
Texas Retina’s Rajiv Anand, MD, presented “Subretinal AGTC-501 Gene Therapy for XLRP: 12-Month Interim Safety & Efficacy Results of the Randomized Controlled Multicenter Phase II Skyline Trial” at the 2024 Annual Meeting
read more
July is UV Safety Month — Debunking Seven Common Myths About Sunglasses
When most people think of UV protection, they think of their skin and sunscreen. Did you know that long-term exposure to bright sunlight may also increase your risk of eye disease? July
read more Dr. Abbey Presents GALE Study Data at the Association for Research in Vision and Ophthalmology
At this year’s ARVO 2024, the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO), Texas Retina’s Dr. Abbey presented 36-month data from the GALE study of pegcetacoplan (brand
read more Texas Retina Associates Participating in Phase III Clinical Trial for Choroidal Melanoma
Under the leadership of principal investigator Timothy Fuller, MD, Texas Retina is now participating in the Phase III AU-011 clinical trial (CoMpass) for treatment of small choroidal (ocular) melanoma. Together with Aura
read more
Monitoring Age-related Macular Degeneration at Home
As the leading cause of vision loss in older adults, age-related macular degeneration (AMD) is the most common reason patients are referred to Texas Retina. It happens when the central part of
read more
Protect Your Eyes as You Enjoy the April 8 Great American Eclipse
On April 8, 2024, North America will witness a rare total solar eclipse as the moon passes between the sun and the Earth, briefly blocking the sun’s rays for several minutes and darkening
read more
Honoring Our Physicians
Tomorrow, March 30, is National Doctor’s Day. At Texas Retina, we celebrate all 16 of our physicians as well as all of the physicians who care for our patients and communities. Thank
read more
Texas Retina Associates Led the Way at the 2024 VisionWalk to Benefit the Foundation Fighting Blindness
This past Saturday, Texas Retina Associates sponsored and participated in the 2024 Dallas-Fort Worth VisionWalk to benefit the Foundation Fighting Blindness and was recognized as the “Largest Team.” Our “Walk Stars” came
read more